The Division of Hematologic Malignancies within MSK’s Department of Medicine is dedicated to treating patients with a variety of blood cancers, as well as some benign hematologic diseases. Our physicians and scientists are central players in advancing translational and clinical research and establishing the standard of care for patients with hematologic cancers.

The Division of Hematologic Malignancies includes the:

• Adult Bone Marrow Transplant Service
• Cellular Therapy Service
• Hematology Service
• Leukemia Service
• Lymphoma Service
• Myeloma Service

A Note From the Division Head

The Division of Hematologic Malignancies in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK) houses world-renowned leaders in blood cancer as well as benign hematologic conditions. Our physicians are experts in leukemia, lymphoma, multiple myeloma, stem cell transplants, cellular therapies, and hematology. Close collaboration between our doctors and scientists allows us to provide patients with top-quality clinical care while we develop groundbreaking therapies to prevent, control, and ultimately cure cancer. It is a privilege to work closely with this talented group of colleagues and allied professionals, all united in our mission to help patients.

Our division has a long history of innovation. We pioneered the first bone marrow transplant from an unrelated donor in 1979. Today, our doctors and clinical staff perform stem cell transplants in more than 500 people each year and administer cellular therapies, including FDA-approved and investigational chimeric antigen receptor (CAR) T cell therapies, in more than 100 people annually. Every patient at MSK receives comprehensive testing to match them with the most effective treatment. Our care teams harness this information to come up with a holistic treatment plan that not only addresses our patients’ physical well-being but also their mental and emotional needs. Moreover, we deliver high-quality care for patients with blood cancer both at our Manhattan sites and in our Regional Care Network.

Our robust clinical trial program offers people with blood cancer and benign hematologic conditions access to the latest detection methods and treatments that often ultimately establish global standards of care. We also operate specialized clinical programs to ensure continuous progress and to better meet the needs of our patients:

• The Program for Drug Development in Leukemia offers patients the most advanced treatments available for acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia through participation in early-phase clinical trials.
• The Center for Hematologic Malignancies unites multidisciplinary specialists across MSK to increase our fundamental understanding of how blood cancers develop and spread, spurring investigations into novel therapies.
• The Clonal Hematopoiesis Program is one of the first programs of its kind to manage people with clonal hematopoiesis, a condition caused by genetic mutations in blood-forming stem cells. People with this condition have a higher risk of developing blood cancers and other diseases.

Our division maintains a rapid pace of innovation in all areas of blood cancer research and treatment. I invite you to explore our clinical programs, current trials, and research initiatives across basic, translational, and clinical research.

Ivan Maillard, MD, PhD
Head of the Division of Hematologic Malignancies